EXTON, Pa., May 27, 2005 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM) today announced that it will present at the Friedman Billings Ramsey 9th Annual Growth Investor Conference, at 8:20 a.m. Eastern Time on Thursday, June 2nd. The conference is being held at the Millennium Broadway Hotel in New York City.
ViroPharma's presentation will be webcast live for investors through www.viropharma.com, and available for replay for a period of 14 days following the conference.
About ViroPharma Incorporated
ViroPharma Incorporated is committed to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(r) Pulvules(r), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information, please download the package insert at at http://www.viropharma.com/docs/pulvules_pi.pdf). ViroPharma currently focuses its drug development activities in viral diseases including cytomegalovirus (CMV) and hepatitis C (HCV). For more information on ViroPharma, visit the company's website at www.viropharma.com.